Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.
Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.
Alector, Inc. has a 1-year low of $3.69 and a 1-year high of $8.90. The stock has a market capitalization of $368.22 million, a price-to-earnings ratio of -2.19 and a beta of 0.66.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company ...
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to ...